PriMera Scientific Surgical Research and Practice (ISSN: 2836-0028)

Review Article

Volume 8 Issue 1

Advancing ADHD Treatment Through Integrative Formulations and Personalized Administration Protocols

Christina Rahm*

July 02, 2026

View PDF

Abstract

Advancing ADHD Treatment Through Integrative Formulations and Personalized Administration Protocols explores a novel approach to ADHD management that moves beyond traditional neurotransmitter-focused therapies. ADHD is described as a complex and heterogeneous neurodevelopmental condition influenced not only by dopamine and norepinephrine pathways but also by metabolic, inflammatory, nutritional, and environmental factors. Current stimulant-based treatments, while effective for some individuals, often present limitations including side effects, inconsistent outcomes, lack of personalization, and challenges with long-term adherence.

The paper introduces a patented dual-formulation model delivered through a staged administration protocol. The first formulation targets neurochemical balance and executive function through ingredients that support dopaminergic signaling, cognitive performance, and neuroprotection. The second formulation addresses systemic and environmental contributors to ADHD by supporting metabolic regulation, mineral balance, and broader physiological stability. A defining feature of the model is its event-based timing strategy, aligning supplementation with cognitive demands and emphasizing personalized administration.

Supporting literature highlights ADHD’s association with systemic dysregulation, including inflammation, oxidative stress, gut-brain interactions, sleep disruption, and metabolic imbalance. Evidence is presented to support the biological plausibility of both formulations, along with preliminary observational data suggesting improvements in focus, task completion, and stress tolerance without stimulant-related adverse effects.

Overall, the patented framework proposes an integrative, precision-oriented model that complements existing therapies rather than replacing them. By translating emerging neuroscience and systems-biology research into a structured protocol, the approach aims to bridge gaps between scientific insight and practical clinical application while contributing to the evolving landscape of personalized ADHD treatment.

References

  1. Akgun EE, Uzumcu M and Bello NT. “Central nervous system stimulants and drugs that suppress appetite”. In Side Effects of Drugs Annual. Elsevier 46 (2024): 547-561.
  2. Antolini G and Colizzi M. “Where do neurodevelopmental disorders go? Casting the eye away from childhood towards adulthood”. In Healthcare. MDPI 11.7 (2023): 1015.
  3. Bond M., et al. “Vitamin D levels in children and adolescents with chronic tic disorders: a multicentre study”. European Child & Adolescent Psychiatry 31.8 (2022): 1-12.
  4. Capuzzi E., et al. “Biological predictors of treatment response in adult attention deficit hyperactivity disorder (ADHD): A systematic review”. Journal of Personalized Medicine 12.10 (2022): 1742.
  5. Dash S, Syed YA and Khan MR. “Understanding the role of the gut microbiome in brain development and its association with neurodevelopmental psychiatric disorders”. Frontiers in Cell and Developmental Biology 10 (2022): 880544.
  6. Dassanayake TL., et al. “Dose–response effect of L-theanine on psychomotor speed, sustained attention, and inhibitory control: a double-blind, placebo-controlled, crossover study”. Nutritional neuroscience 26.11 (2023): 1138-1146.
  7. Heng YY., et al. “Heavy metals and neurodevelopment of children in low and middle-income countries: A systematic review”. PLoS One 17.3 (2022): e0265536.
  8. Kumar Aakash., et al. “Magnesium (Mg2+): Essential mineral for neuronal health: From cellular biochemistry to cognitive health and behavior regulation”. Current Pharmaceutical Design 30.39 (2024): 3074-3107.
  9. Leisman G and Melillo R. “Front and center: Maturational dysregulation of frontal lobe functional neuroanatomic connections in attention deficit hyperactivity disorder”. Frontiers in neuroanatomy 16 (2022): 936025.
  10. McAllister MJ., et al. “Impact of L-theanine and L-tyrosine on markers of stress and cognitive performance in response to a virtual reality based active shooter training drill”. Stress 27.1 (2024): 2375588.
  11. Mowlem FD., et al. “Best practice recommendations and considerations for designing and electronically implementing event-driven diaries in clinical trials”. npj Digital Medicine 8.1 (2025): 745.
  12. Panaiotov S., et al. “Zeolite and neurodegenerative diseases”. Molecules 29.11 (2024): 2614.
  13. Perugi G, De Rosa U and Barbuti M. “What value do norepinephrine/dopamine dual reuptake inhibitors have to the current treatment of adult attention deficit hyperactivity disorder (ADHD) treatment armamentarium?”. Expert Opinion on Pharmacotherapy 23.18 (2022): 1975-1978.
  14. Quenneville AF., et al. “Anxiety disorders in adult ADHD: A frequent comorbidity and a risk factor for externalizing problems”. Psychiatry research 310 (2022): 114423.
  15. Usui N, Kobayashi H and Shimada S. “Neuroinflammation and oxidative stress in the pathogenesis of autism spectrum disorder”. International journal of molecular sciences 24.6 (2023): 5487.
  16. Wang Y., et al. “The Multidimensional Dynamic Feedback Model: A Comprehensive Framework for Understanding and Managing Attention-Deficit/Hyperactivity Disorder”. Children 12.3 (2025): 303.